Metabolic burden measured by 18F-fluorodeoxyglucose positron emission tomography/Computed tomography is a prognostic factor in patients with small cell lung cancer

Cancer Research and Treatment

Volumn 46, Issue 2, 2014, Pages 165-171

  Kim, Mi Hyun ^a,b   Lee, Ji Seok ^a   Mok, Jeong Ha ^a   Lee, Kwangha ^a   Kim, Ki Uk ^a   Park, Hye Kyung ^a   Kim, Seong Jang ^a   Lee, Min Ki ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Neoplasms; Positron emission tomography and computed tomography; Prognosis; Small cell lung carcinoma; Tumor burden

Indexed keywords

CISPLATIN; CYTOKERATIN 19 FRAGMENT; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; NEURON SPECIFIC ENOLASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OVERALL SURVIVAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84900438618     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2014.46.2.165     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Aisner J. Extensive-disease small-cell lung cancer: the thrill of victory: the agony of defeat. J Clin Oncol. 1996;14:658-65.
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-7.
4. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28:173-85.
5. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990;8:1563-74.
6. Pillot G, Siegel BA, Govindan R. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review. J Thorac Oncol. 2006;1:152-9.
7. max) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6-12.
8. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 2007; 73:1151-7.
9. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-300.
10. Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res. 2009;15:2426-32.
11. Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, et al. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73:332-7.
12. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
13. Um SW, Kim H, Koh WJ, Suh GY, Chung MP, Kwon OJ, et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol. 2009;4:1331-6.
14. Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest. 1997;112(4 Suppl):251S-8S.
15. Park S, Moon SH, Park LC, Hwang DW, Ji JH, Maeng CH, et al. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. Am J Hematol. 2012;87:937-40.
16. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of disease. Philadelphia: Elsevier Saunders; 2009.
17. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol. 2005;23:5117-25.
18. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Harita S, et al. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol. 2005;16:1817-23.
19. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Oze I, Ochi N, et al. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann Oncol. 2009;20:829-34.
20. Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009;4:311-7.
21. Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res. 2005;11:5534-8.
22. Simon GR, Turrisi A; American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):324S-39S.